Original Articles

Managing Prolactinoma During Pregnancy

Abstract

Objective:Prolactinomas are the most common pituitary tumors in pregnant women. We conducted this study on pregnant women with prolactinoma to determine their clinical symptoms and signs and eventual necessity to medical therapy.
Materials and methods:A descriptive study was performed on 85 pregnant women with prolactinoma.Patients were followed up by physical examination, imaging, and perimetry for diagnosis of visual field defect. If tumor was increased in size perimetry was performedin order to determine eventual visual field defect (VFD). Patients with progressive visual field defect had absolute indication for trans sphenoidal surgery (TSS).In other cases with progressive enlargement of adenoma size but without VFD bromocriptine was administered. Patients without increasing adenoma size were just followed up.
Results:In this study 72 patients (84%) had microadenomas, 7 patients (8%) had macroadenomas without previous medical or surgical therapy and 6 patients (7%) had macroadenomas with previous medical therapy with bromocriptine. Totally 20 patients (23 %) had tumor enlargement during pregnancy and was symptomatic in 7 patients (8.2%). There was significant difference between 3 groups according to incidence of symptomatic tumor enlargement.(p<0.05)Conclusion:Macroprolactinomas are more likely to enlarge during pregnancy than microprolactinomas. In our study conservative management was successfully done in all patients without surgery or medical therapy.

Melmed S, Braunstein GD, Chang RJ, Becker DP. Pituitary tumors secreting growth hormone and prolactin.Ann Intern Med 1986; 105: 238–53.

Kredentser JV, Hoskins CF, Scott JZ. Hyperprolactinemia—a significant factor in female infertility. Am J ObstetGynecol 1981; 139: 264–7.

Molitch ME. Pituitary incidentalomas.Endocrinol Metab Clin North Am 1997; 26: 725–40.

Molitch ME. Pituitary tumors and pregnancy. Growth Hormone & IGF Research 2003; 13: S38–44.

Kulvinder K, Mandeep S, Virk S. Prolactinomas in infertility. Reviews in Gynaecological Practice 2003; 3: 180–7.

Greer ME, Moraczewski T, Rakoff JS. Prevalence of hyperprolactinemia in anovulatory women. Obstet Gynecol 1980; 56: 65–9.

Molitch ME. Pregnancy and the hyperprolactinemicwoman. N Engl J Med 1985; 312: 1364–70.

Ciccarelli E, Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs 1996; 51: 954–65.

Ricci E, Parazzini F, Motta T,Ferrari CI, Colao A, Clavenna A, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002; 16: 791–3.

Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab1989; 68: 412–8.

Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999; 44: 1121–6.

Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Ann Intern Med 1994; 121: 473–7.

Bronstein MD. Prolactinomas and pregnancy. Pituitary 2005; 8: 31–8.

Weiss MH. Treatment options in the management of prolactin–secreting pituitary tumors. ClinNeurosurg 1986; 33: 547–52.

Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 1982; 247: 1589–91.

Imran SA, Ur E, Clarke DB. Managing prolactin– secreting adenomas during pregnancy. Canadian Family Physician 2007; 53: 653–8.

Files
IssueVol 4, No 2 (June 2010) QRcode
SectionOriginal Articles
Keywords
prolactinoma pregnancy Transsphenoidal surgery Bromocriptine

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Azar M, Nikoobakht M. Managing Prolactinoma During Pregnancy. J Family Reprod Health. 2010;4(2):83-86.